Kelly CRISPR & Gene Editing Technology ETF
Not enough financial coverage to compute a composite score for XDNA. This is typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available data still render below.
Company
The adviser employs a “passive management” investment approach designed to track the total return performance of the index. The index is a rules-based index that consists of the stocks or corresponding depositary receipts of companies engaged in the creation, development, production, operation, provision, distribution, ownership, servicing, licensing, leasing or franchising of at least one of the DNA Modification Technology Business. The fund invests at least 80% of its net assets in DNA Modification Technology Companies.
- IPO
- 2022
Price Chart
Valuation
- Market Cap
- $2.58M
- Div Yield
- 0.13%
Performance & Tape
- 52W High
- $11.83
- 52W Low
- $5.87
- 50D MA
- $7.01
- 200D MA
- $8.43
- Beta
- 0.00
- Avg Volume
- 5.04K
Get TickerSpark's AI analysis on XDNA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our XDNA Coverage
We haven't published any research on XDNA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate XDNA Report →